More recently semaglutide was approved for treatment of obesity and overweight; compared to the previous GLP-1R agonists, it offers the significant benefits of once-weekly (instead of daily) treatment and a superior capacity to lower body weight (for a detailed review on the history of GLP-1R agonist drugs developments and effects on body weight see [19]). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.